Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus etoposide and platinum vs placebo in extensive-stage small cell lung cancer
CTR20191139Phase 3Active
- Sponsor
- Junshi Biosciences
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in small cell lung cancer (SCLC), sponsored by Junshi Biosciences. Started Jul 2019; status: active.
02
Drugs
toripalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20191139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191139.